AIM Vaccine Co., Ltd. (6660.HK)

Descripción

AIM Vaccine Co., Ltd. researches, develops, manufactures, and commercializes of vaccine products for human use in the People's Republic of China. The company's product pipeline includes tetravalent meningococcal conjugate vaccine, that is in phase IV clinical trials indicated for meningococcal disease 13-Valent pneumonia Conjugate and 23-valent pneumonia Polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine which is in phase III clinical trials to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, that is in phase II trials for the treatment of meningococcal disease; EV71-CA16 Bivalent HFMD vaccine. In addition, the company develops 20-valent and 24-valent pneumonia conjugate vaccine, haemophilus influenzae type b conjugate vaccine, absorbed tetanus vaccine, quadrivalent influenza virus vaccine (MDCK Cells), and human diploid rabies vaccine. Further, it offers hexavalent meningococcal vaccine to treat meningococcal disease; hexavalent group b streptococcus polysaccharide conjugate vaccine; mRNA human rabies vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; diphtheria, tetanus and pertussis and haemophilus influenzae type b, and diphtheria, tetanus and acellular pertussis combination vaccine for the treatment of DTP; and recombinant group b meningococcal vaccine to treat meningococcal disease. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. The company was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.